Intellia Therapeutics presents additional results from Phase 3 HAELO trial. Jun. 14, 2026, 02:35 PM Intellia Therapeutics (NTLA) presented additional positive results from the global Phase 3 HAELO clinical trial of lonvo-z for hereditary angioedema, HAE, in a late-breaking oral presentation at the European Academy of Allergy & Clinical Immunology, EAACI, Annual Congress 2026 in Istanbul, Turkiye. Results from the trial were simultaneously published in the New England Journal of Medicine. Today's presentation and publication also included supplemental demographics, data and analyses, including: A time plot showing that the mean monthly attack rate for patients receiving lonvo-z through the data cutoff was well below the reported rate in prescreening while patients were receiving standard-of-care therapy; Patient-level data demonstrating that all patients in the lonvo-z arm experienced attack-rate reductions from baseline during weeks 5 to 28; An analysis showing that meaningful attack-rate reductions were observed for all evaluated subgroups; A breakdown showing that 20% of the patients who enrolled in HAELO reported having complete disease control as their best response to prior long-term prophylaxis therapies; and A plasma kallikrein time plot showing that protein levels decreased substantially by the first measurement, reached a steady state by week 5 and remained stable through the data cutoff. * Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. * Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter. Published first on TheFly - the ultimate source for real-time, market-moving breaking financial news. Try Now>> Read More on NTLA:

Intellia Therapeutics has raised $120 million in a Series C round led by Ribbit Capital, valuing the biotechnology company at $1.45 billion. Sequoia and Kleiner Perkins participated as existing investors, whilst Emerson Collective joined as a new backer. The pre-revenue startup is developing "Mathematical Superintelligence", focusing on advanced reasoning that eliminates AI hallucinations by requiring outputs in verifiable Lean4 programming language. Its Aristotle model achieved top-level performance at the International Mathematical Olympiad in July alongside Google and OpenAI. Founded in 2023, Harmonic has raised $295 million across three rounds in 14 months. The company currently offers Aristotle via free API and plans future commercialisation in safety-critical sectors including aerospace, automotive and finance.

Cathie Wood's Ark Invest purchased shares of three stocks on Tuesday as they tumbled: Shopify, Intellia Therapeutics and GeneDX Holdings, which fell between 4% and 49%. Shopify dropped 16% despite reporting strong first-quarter results, with revenue rising 34% and adjusted net income surging 44%. The decline followed cautious guidance predicting revenue growth deceleration to the high twenties percentage-wise in the current quarter. Despite trading at over 50 times forward earnings, Shopify has maintained double-digit free cash flow margins for 12 consecutive quarters. Intellia Therapeutics, a CRISPR-based gene-editing therapy developer, declined 4%. GeneDX Holdings also attracted Wood's interest. These were the only three stocks Ark Invest purchased during Tuesday's trading session, with Wood adding to existing positions in all three companies.